Luminex Corporation to Present at UBS Global Life Sciences Conference

AUSTIN, Texas, Sept. 9 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX) today announced that management will present at UBS Global Life Sciences Conference to be held September 20 - 22, 2010, in New York City, New York.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 8:00 a.m. Eastern time on Wednesday, September 22, 2010.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived for six months on the website using the 'replay' link.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP(R) multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at www.luminexcorp.com.

SOURCE Luminex Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED